PT  - JOURNAL ARTICLE
AU  - Yun Zhu
AU  - Zhaowei Teng
AU  - Lirong Yang
AU  - Shuanglan Xu
AU  - Jie Liu
AU  - Yirong Teng
AU  - Qinggang Hao
AU  - Dake Zhao
AU  - Xiaolan Li
AU  - Sheng Lu
AU  - Yong Zeng
TI  - Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
AID  - 10.1101/2020.06.22.20136531
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.22.20136531
4099  - http://medrxiv.org/content/early/2020/06/29/2020.06.22.20136531.short
4100  - http://medrxiv.org/content/early/2020/06/29/2020.06.22.20136531.full
AB  - BACKGROUND Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of remdesivir is controversial.METHODS We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study is registered at INPLASY (INPLASY202060046).RESULTS Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05–1.34], I2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44–0.92], I2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63–0.94], I2 = 0.0%, P = 0.716).CONCLUSION Remdesivir is efficacious and safe for the treatment of COVID-19.TRIAL REGISTRATION NUMBER This study is registered at the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202060046).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is registered at INPLASY (INPLASY202060046).Funding StatementThis study was supported by the Joint Special Fund (grants 2018FE001(-175) and 2018FE001(-174)); and the Yunnan Health Training Project of High-level Talents (grants H-2017064 and H-2017028).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article.